Trading
Data
Solutions
Insights
About
Neurona Therapeutics is a company that strives to develop clinical-stage biotherapeutic treatments for neurological disorders with a focus on advancing regenerative cell therapy candidates. The company researches allogeneic therapies that come from stem cells harvested from donors. Neurona's proprietary therapy NRTX-1001 aims to reverse the effects of Alzheimer’s disease and other nervous system disorders. Neurona Therapeutics was founded by Arnold Kriegstein and Cory R. Nicholasin in 2008 and is headquartered in San Francisco, CA.
Neurona Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Neurona Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Neurona Therapeutics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 2/8/2024 | Series E | $120MM raised | $XXX.XX | $XXX.XX |
| 3/19/2021 | Series D | $72.01MM raised | $XXX.XX | $XXX.XX |
| 11/18/2019 | Series C | $15.03MM raised | $XXX.XX | $XXX.XX |
| 2/8/2018 | Series B | $10.04MM raised | $XXX.XX | $XXX.XX |
| 12/1/2015 | Series A | $23.5MM raised | $XXX.XX | $XXX.XX |
